InsidersTradesSigma
Follow the Amgen Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €233.8bn. The latest transaction was reported on 6 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Derek Miller. The full history is free.
Analysts rate Amgen Inc. Buy (bullish), based on 29 analysts. Average price target: US$388.48.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Amgen Inc. is an American biopharmaceutical company focused on the research, development, and manufacturing of medications. It primarily concentrates on oncology, immunology, and cardiovascular diseases.